<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979923</url>
  </required_header>
  <id_info>
    <org_study_id>227/IRB/SZMC/SZH</org_study_id>
    <nct_id>NCT04979923</nct_id>
  </id_info>
  <brief_title>Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial</brief_title>
  <official_title>Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheikh Zayed Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheikh Zayed Medical College</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic&#xD;
      worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over&#xD;
      20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever&#xD;
      followed by cough and dyspnea as well as chest pain in severe cases4. The current&#xD;
      preventative strategies are non-specific10, and current interventions are predominantly&#xD;
      supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local&#xD;
      anesthetics including lidocaine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cough suppression</measure>
    <time_frame>within five minutes of initiation of treatment it will be assessed</time_frame>
    <description>it will be assessed by using cough severity score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correction of hypoxia</measure>
    <time_frame>immediately before and after intervention</time_frame>
    <description>it will be assessed by PaO2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Lidocaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Beclomethasone plus salbutamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs</description>
    <arm_group_label>Beclomethasone plus salbutamol</arm_group_label>
    <arm_group_label>Lidocaine group</arm_group_label>
    <arm_group_label>Salbutamol group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Covid-19 positive&#xD;
&#xD;
          -  Moderate to severe ARDS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with COPD or taking bronchodilators and steroids for chronic respiratory&#xD;
             illnesses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>sairah s sadaf, FCPS</last_name>
    <phone>0092 689230165</phone>
    <phone_ext>245</phone_ext>
    <email>sairahbabar@live.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheikh zayed medical college &amp; hospital</name>
      <address>
        <city>Rahim Yar Khan</city>
        <state>Punjab</state>
        <zip>64200</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>alina a umar, MCPS</last_name>
      <phone>0092 689230165</phone>
      <phone_ext>245</phone_ext>
      <email>alinaumar1@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheikh Zayed Medical College</investigator_affiliation>
    <investigator_full_name>Sairah Sadaf</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

